John Sourbeer
Stock Analyst at UBS
(0.56)
# 4,171
Out of 5,150 analysts
44
Total ratings
33.33%
Success rate
-19.79%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $11 → $13 | $8.74 | +43.02% | 7 | Nov 5, 2025 | |
| ILMN Illumina | Maintains: Neutral | $110 → $120 | $128.97 | -6.96% | 6 | Oct 31, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $320 → $355 | $248.84 | +42.66% | 5 | Oct 24, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $46 → $48 | $46.88 | +1.58% | 5 | Aug 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $110.20 | +117.79% | 2 | Jul 25, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $17.50 | +34.29% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $21.19 | +112.36% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.56 | +28.21% | 3 | Nov 11, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $465.86 | +3.04% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $38.50 | +164.94% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $22.37 | +123.51% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $113.10 | +13.17% | 2 | Jul 27, 2022 |
Cryoport
Nov 5, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $8.74
Upside: +43.02%
Illumina
Oct 31, 2025
Maintains: Neutral
Price Target: $110 → $120
Current: $128.97
Upside: -6.96%
West Pharmaceutical Services
Oct 24, 2025
Maintains: Buy
Price Target: $320 → $355
Current: $248.84
Upside: +42.66%
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $46 → $48
Current: $46.88
Upside: +1.58%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $110.20
Upside: +117.79%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $17.50
Upside: +34.29%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $21.19
Upside: +112.36%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.56
Upside: +28.21%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $465.86
Upside: +3.04%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $38.50
Upside: +164.94%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $22.37
Upside: +123.51%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $113.10
Upside: +13.17%